NCT05273359 - Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

January 31, 2025

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Benralizumab

15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.

OTHER

Benralizumab placebo

15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.

OTHER

Comparison (control) group; no intervention

15 subjects (\<150 eosinophils/microliter) will not receive any intervention.